Toward an injectable continuous osmotic glucose sensor

Erik Johannessen (Corresponding Author), Olga Krushinitskaya, Andrey Sokolov, Philipp Häfliger, Arno Hoogerwerf, Christian Hinderling, Kari Kautio, Jaakko Lenkkeri, Esko Strömmer, Vasily Kondratyev, Tor Inge Tønnessen, Tom Eirik Mollnes, Henrik Jakobsen, Even Zimmer, Bengt Akselsen

    Research output: Contribution to journalArticleScientificpeer-review

    25 Citations (Scopus)

    Abstract

    Background: The growing pandemic of diabetes mellitus places a stringent social and economic burden on the society. A tight glycemic control circumvents the detrimental effects, but the prerogative is the development of new more effective tools capable of longterm tracking of blood glucose (BG) in vivo. Such discontinuous sensor technologies will benefit from an unprecedented marked potential as well as reducing the current life expectancy gap of eight years as part of a therapeutic regime.

    Method: A sensor technology based on osmotic pressure incorporates a reversible competitive affinity assay performing glucose-specific recognition. An absolute change in particles generates a pressure that is proportional to the glucose concentration. An integrated pressure transducer and components developed from the silicon micro- and nanofabrication industry translate this pressure into BG data.

    Results: An in vitro model based on a 3.6 × 8.7 mm large pill-shaped implant is equipped with a nanoporous membrane holding 4–6 nm large pores. The affinity assay offers a dynamic range of 36–720 mg/dl with a resolution of ±16 mg/dl. An integrated 1 × 1 mm2 large control chip samples the sensor signals for data processing and transmission back to the reader at a total power consumption of 76 µW.

    Conclusions: Current studies have demonstrated the design, layout, and performance of a prototype osmotic sensor in vitro using an affinity assay solution for up to four weeks. The small physical size conforms to an injectable device, forming the basis of a conceptual monitor that offers a tight glycemic control of BG.
    Original languageEnglish
    Pages (from-to)882-892
    Number of pages11
    JournalJournal of diabetes science and technology
    Volume4
    Issue number4
    DOIs
    Publication statusPublished - 2010
    MoE publication typeA1 Journal article-refereed

    Fingerprint

    Glucose sensors
    Glucose
    Blood Glucose
    Assays
    Injections
    Sensors
    Microtechnology
    Technology
    Pressure Transducers
    Pressure
    Osmotic Pressure
    Pandemics
    Silicon
    Life Expectancy
    Blood
    Pressure transducers
    Microfabrication
    Diabetes Mellitus
    Industry
    Medical problems

    Keywords

    • CGM
    • injectable
    • microtechnology
    • nanotechnology
    • osmotic
    • pressure

    Cite this

    Johannessen, E., Krushinitskaya, O., Sokolov, A., Häfliger, P., Hoogerwerf, A., Hinderling, C., ... Akselsen, B. (2010). Toward an injectable continuous osmotic glucose sensor. Journal of diabetes science and technology, 4(4), 882-892. https://doi.org/10.1177/193229681000400417
    Johannessen, Erik ; Krushinitskaya, Olga ; Sokolov, Andrey ; Häfliger, Philipp ; Hoogerwerf, Arno ; Hinderling, Christian ; Kautio, Kari ; Lenkkeri, Jaakko ; Strömmer, Esko ; Kondratyev, Vasily ; Tønnessen, Tor Inge ; Mollnes, Tom Eirik ; Jakobsen, Henrik ; Zimmer, Even ; Akselsen, Bengt. / Toward an injectable continuous osmotic glucose sensor. In: Journal of diabetes science and technology. 2010 ; Vol. 4, No. 4. pp. 882-892.
    @article{59860dd25770402f972dc1eedf60f754,
    title = "Toward an injectable continuous osmotic glucose sensor",
    abstract = "Background: The growing pandemic of diabetes mellitus places a stringent social and economic burden on the society. A tight glycemic control circumvents the detrimental effects, but the prerogative is the development of new more effective tools capable of longterm tracking of blood glucose (BG) in vivo. Such discontinuous sensor technologies will benefit from an unprecedented marked potential as well as reducing the current life expectancy gap of eight years as part of a therapeutic regime.Method: A sensor technology based on osmotic pressure incorporates a reversible competitive affinity assay performing glucose-specific recognition. An absolute change in particles generates a pressure that is proportional to the glucose concentration. An integrated pressure transducer and components developed from the silicon micro- and nanofabrication industry translate this pressure into BG data.Results: An in vitro model based on a 3.6 × 8.7 mm large pill-shaped implant is equipped with a nanoporous membrane holding 4–6 nm large pores. The affinity assay offers a dynamic range of 36–720 mg/dl with a resolution of ±16 mg/dl. An integrated 1 × 1 mm2 large control chip samples the sensor signals for data processing and transmission back to the reader at a total power consumption of 76 µW.Conclusions: Current studies have demonstrated the design, layout, and performance of a prototype osmotic sensor in vitro using an affinity assay solution for up to four weeks. The small physical size conforms to an injectable device, forming the basis of a conceptual monitor that offers a tight glycemic control of BG.",
    keywords = "CGM, injectable, microtechnology, nanotechnology, osmotic, pressure",
    author = "Erik Johannessen and Olga Krushinitskaya and Andrey Sokolov and Philipp H{\"a}fliger and Arno Hoogerwerf and Christian Hinderling and Kari Kautio and Jaakko Lenkkeri and Esko Str{\"o}mmer and Vasily Kondratyev and T{\o}nnessen, {Tor Inge} and Mollnes, {Tom Eirik} and Henrik Jakobsen and Even Zimmer and Bengt Akselsen",
    year = "2010",
    doi = "10.1177/193229681000400417",
    language = "English",
    volume = "4",
    pages = "882--892",
    journal = "Journal of diabetes science and technology",
    issn = "1932-2968",
    publisher = "Diabetes Technology Society",
    number = "4",

    }

    Johannessen, E, Krushinitskaya, O, Sokolov, A, Häfliger, P, Hoogerwerf, A, Hinderling, C, Kautio, K, Lenkkeri, J, Strömmer, E, Kondratyev, V, Tønnessen, TI, Mollnes, TE, Jakobsen, H, Zimmer, E & Akselsen, B 2010, 'Toward an injectable continuous osmotic glucose sensor', Journal of diabetes science and technology, vol. 4, no. 4, pp. 882-892. https://doi.org/10.1177/193229681000400417

    Toward an injectable continuous osmotic glucose sensor. / Johannessen, Erik (Corresponding Author); Krushinitskaya, Olga; Sokolov, Andrey; Häfliger, Philipp; Hoogerwerf, Arno; Hinderling, Christian; Kautio, Kari; Lenkkeri, Jaakko; Strömmer, Esko; Kondratyev, Vasily; Tønnessen, Tor Inge; Mollnes, Tom Eirik; Jakobsen, Henrik; Zimmer, Even; Akselsen, Bengt.

    In: Journal of diabetes science and technology, Vol. 4, No. 4, 2010, p. 882-892.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Toward an injectable continuous osmotic glucose sensor

    AU - Johannessen, Erik

    AU - Krushinitskaya, Olga

    AU - Sokolov, Andrey

    AU - Häfliger, Philipp

    AU - Hoogerwerf, Arno

    AU - Hinderling, Christian

    AU - Kautio, Kari

    AU - Lenkkeri, Jaakko

    AU - Strömmer, Esko

    AU - Kondratyev, Vasily

    AU - Tønnessen, Tor Inge

    AU - Mollnes, Tom Eirik

    AU - Jakobsen, Henrik

    AU - Zimmer, Even

    AU - Akselsen, Bengt

    PY - 2010

    Y1 - 2010

    N2 - Background: The growing pandemic of diabetes mellitus places a stringent social and economic burden on the society. A tight glycemic control circumvents the detrimental effects, but the prerogative is the development of new more effective tools capable of longterm tracking of blood glucose (BG) in vivo. Such discontinuous sensor technologies will benefit from an unprecedented marked potential as well as reducing the current life expectancy gap of eight years as part of a therapeutic regime.Method: A sensor technology based on osmotic pressure incorporates a reversible competitive affinity assay performing glucose-specific recognition. An absolute change in particles generates a pressure that is proportional to the glucose concentration. An integrated pressure transducer and components developed from the silicon micro- and nanofabrication industry translate this pressure into BG data.Results: An in vitro model based on a 3.6 × 8.7 mm large pill-shaped implant is equipped with a nanoporous membrane holding 4–6 nm large pores. The affinity assay offers a dynamic range of 36–720 mg/dl with a resolution of ±16 mg/dl. An integrated 1 × 1 mm2 large control chip samples the sensor signals for data processing and transmission back to the reader at a total power consumption of 76 µW.Conclusions: Current studies have demonstrated the design, layout, and performance of a prototype osmotic sensor in vitro using an affinity assay solution for up to four weeks. The small physical size conforms to an injectable device, forming the basis of a conceptual monitor that offers a tight glycemic control of BG.

    AB - Background: The growing pandemic of diabetes mellitus places a stringent social and economic burden on the society. A tight glycemic control circumvents the detrimental effects, but the prerogative is the development of new more effective tools capable of longterm tracking of blood glucose (BG) in vivo. Such discontinuous sensor technologies will benefit from an unprecedented marked potential as well as reducing the current life expectancy gap of eight years as part of a therapeutic regime.Method: A sensor technology based on osmotic pressure incorporates a reversible competitive affinity assay performing glucose-specific recognition. An absolute change in particles generates a pressure that is proportional to the glucose concentration. An integrated pressure transducer and components developed from the silicon micro- and nanofabrication industry translate this pressure into BG data.Results: An in vitro model based on a 3.6 × 8.7 mm large pill-shaped implant is equipped with a nanoporous membrane holding 4–6 nm large pores. The affinity assay offers a dynamic range of 36–720 mg/dl with a resolution of ±16 mg/dl. An integrated 1 × 1 mm2 large control chip samples the sensor signals for data processing and transmission back to the reader at a total power consumption of 76 µW.Conclusions: Current studies have demonstrated the design, layout, and performance of a prototype osmotic sensor in vitro using an affinity assay solution for up to four weeks. The small physical size conforms to an injectable device, forming the basis of a conceptual monitor that offers a tight glycemic control of BG.

    KW - CGM

    KW - injectable

    KW - microtechnology

    KW - nanotechnology

    KW - osmotic

    KW - pressure

    U2 - 10.1177/193229681000400417

    DO - 10.1177/193229681000400417

    M3 - Article

    VL - 4

    SP - 882

    EP - 892

    JO - Journal of diabetes science and technology

    JF - Journal of diabetes science and technology

    SN - 1932-2968

    IS - 4

    ER -

    Johannessen E, Krushinitskaya O, Sokolov A, Häfliger P, Hoogerwerf A, Hinderling C et al. Toward an injectable continuous osmotic glucose sensor. Journal of diabetes science and technology. 2010;4(4):882-892. https://doi.org/10.1177/193229681000400417